DI COSTANZO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 2.342
EU - Europa 1.670
AS - Asia 1.021
SA - Sud America 90
AF - Africa 19
OC - Oceania 7
Totale 5.149
Nazione #
US - Stati Uniti d'America 2.317
RU - Federazione Russa 605
PL - Polonia 424
SG - Singapore 309
CN - Cina 242
IT - Italia 157
HK - Hong Kong 144
IE - Irlanda 120
VN - Vietnam 114
SE - Svezia 105
BR - Brasile 72
FI - Finlandia 70
KR - Corea 68
FR - Francia 46
DE - Germania 42
IN - India 39
JO - Giordania 34
GB - Regno Unito 31
ID - Indonesia 18
JP - Giappone 15
CA - Canada 13
ES - Italia 12
UA - Ucraina 12
AT - Austria 11
BD - Bangladesh 11
IQ - Iraq 8
AR - Argentina 7
AU - Australia 7
BE - Belgio 7
CH - Svizzera 7
MX - Messico 7
NL - Olanda 7
ZA - Sudafrica 7
MA - Marocco 4
PK - Pakistan 4
SA - Arabia Saudita 4
VE - Venezuela 4
IL - Israele 3
LT - Lituania 3
UZ - Uzbekistan 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
CL - Cile 2
HR - Croazia 2
NG - Nigeria 2
PY - Paraguay 2
UY - Uruguay 2
AL - Albania 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
GR - Grecia 1
HN - Honduras 1
KE - Kenya 1
KH - Cambogia 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TN - Tunisia 1
TR - Turchia 1
Totale 5.149
Città #
Santa Clara 504
Warsaw 423
Ashburn 314
Singapore 217
Fairfield 209
Hong Kong 123
Dublin 119
Chandler 116
San Jose 102
Seattle 85
Woodbridge 77
Cambridge 68
Seoul 68
Houston 67
Wilmington 65
Beijing 53
Helsinki 49
Lawrence 43
Altamura 42
Ann Arbor 41
Council Bluffs 40
Buffalo 39
Moscow 31
Princeton 31
Ho Chi Minh City 28
Hanoi 27
Florence 25
Los Angeles 25
Boston 24
Lauterbourg 24
Munich 23
Mumbai 21
New York 21
Shanghai 20
Dong Ket 18
Hefei 18
Boardman 17
Dallas 17
Jakarta 16
Pisa 16
Rome 14
Medford 12
San Diego 12
The Dalles 12
Paris 11
Tokyo 11
Turku 11
Clifton 10
Vienna 10
Orem 9
Shenzhen 9
Da Nang 8
Redondo Beach 8
Bern 7
Brussels 7
Pune 7
Redwood City 7
Barcelona 6
Frankfurt am Main 6
Johannesburg 6
London 6
Norwalk 6
São Paulo 6
Toronto 6
Atlanta 5
Barnet 5
Guangzhou 5
Melbourne 5
Biên Hòa 4
Bremen 4
Curitiba 4
Falls Church 4
Hillsboro 4
Kent 4
Milan 4
Yubileyny 4
Amman 3
Amsterdam 3
Baghdad 3
Charlotte 3
Chennai 3
Lucca 3
Mexico City 3
Mykolayiv 3
Nuremberg 3
Phoenix 3
Suzhou 3
Tashkent 3
Abidjan 2
Avellaneda 2
Barbacena 2
Bengaluru 2
Cantu 2
Casablanca 2
Cinisello Balsamo 2
Conversano 2
Dnipro 2
Elk Grove Village 2
Frankenmuth 2
Hangzhou 2
Totale 3.585
Nome #
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy 332
Adjuvant chemotherapy in completely resected gastric cancer: A randomized phase III trial conducted by GOIRC 284
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification 267
hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma 257
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 249
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients 232
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 223
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 201
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 199
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study 193
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 190
Physical exercise and eating habits in cancer survivors 182
Circulating tumour cells in colorectal cancer 179
Effects of a home based exercise rehabilitation program for cancer survivors 178
Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors 176
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 175
A transcriptomic approach reveals selective ribosomal remodelling in the tumour versus the stromal compartment of metastatic colorectal cancer 159
Temperament and character traits associated with health-related quality of life in cancer patients 158
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. 154
Regorafenib also can cause osteonecrosis of the jaw 144
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas 143
Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status 140
A multi-center study on the surgical management of metastatic disease to adrenal glands 137
Bevacizumab in non-small cell lung cancer 136
Phase II study of 5-FU plus 6-S-leucovorin (6S-LV) in advanced colorectal cancer 132
Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: A restrospective analysis from the ObservEr study 132
ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) Trial: comparison of a sequential treatment with irinotecan (cpt-11) + 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer 129
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 101
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 35
Totale 5.217
Categoria #
all - tutte 15.250
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.250


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202159 0 0 0 0 0 0 0 0 0 0 32 27
2021/2022224 8 17 21 8 5 15 5 15 19 13 31 67
2022/2023608 57 131 33 27 38 110 76 36 68 5 15 12
2023/2024225 3 19 28 12 10 50 15 47 2 16 12 11
2024/20251.542 45 151 79 285 437 206 22 66 75 46 64 66
2025/20261.454 175 197 88 87 181 75 250 88 119 136 58 0
Totale 5.217